About Transgene Biotek Limited.
Data last updated:
Transgene Biotek Limited. is a public limited company based in Ida Bollaram, Telangana, India. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 01 March 1990 and has been in existence for over 36 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L85195TG1990PLC011065. Its GSTIN is 36AABCT3840P2ZX (Telangana). The company holds 4 GST registrations, of which 1 is active. Its shares are listed on BSE: 526139.
The company has an authorised share capital of ₹76 Cr and a paid-up capital of ₹75.77 Cr. It is led by directors including Kollipara Koteswara Rao (Managing Director) and Sujana Kadiam.
Its last annual general meeting (AGM) was held on 30 December 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No:69 & 70 Ida Bollaram Sangareddy District., Telangana, India – 502325.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹21 Lakh, a decline of 19.2% compared to the previous year. For the same year it recorded a net loss of ₹1.65 Cr and EBITDA of -₹54 Lakh (EBITDA margin -257.1%).
Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Transgene Biotek. As per MCA filings, the company has open charges of ₹12.57 Cr and satisfied charges of ₹9.88 Cr on record. Court records list 41 cases involving the company, including 23 filed by the company and 18 filed against it; 3 cases are pending. The company has 56 deals on record (54 market trades, 1 acquisition, 1 funding round); the latest was in December 2023. Its 3 peer companies in the Biotechnology industry (Biotechnology), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 1 larger and 2 smaller; the largest is Dozo Pharma Private Limited with revenue of ₹1.06 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website transgenebiotek.com.
Company details
CIN history
Transgene Biotek Limited has one previous CIN (Corporate Identification Number): L85195AP1990PLC011065. The current CIN is L85195TG1990PLC011065, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L85195TG1990PLC011065 | Current |
| L85195AP1990PLC011065 | Previous |
Contact details
Transgene Biotek Limited.'s registered office is in Ida Bollaram, Telangana. Its website is transgenebiotek.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressPlot No:69 & 70 Ida Bollaram Sangareddy District., Telangana, India – 502325
- IndustryLife Sciences, Biotechnology
To see the full contact details of Transgene Biotek Limited., buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Transgene Biotek Limited operates one associated brand: Transgene Biotek. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Immunotherapies and drug delivery solutions for cancer are developed. | transgenebiotek.com |
Business activity
The main business activity of Transgene Biotek Limited is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Transgene Biotek Limited., buy the company report.
Financials of Transgene Biotek Limited.
FY 2025-26 filings availableTransgene Biotek Limited. reported revenue of ₹21 Lakh (down 19.2% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.21 | 0.26 | 0.23 | 0.06 | 0.09 | 0.17 | 0.00 |
| Revenue growth | -19.2% | +13.0% | +283.3% | -33.3% | -47.1% | - | - |
| EBITDA | (0.54) | (1.13) | (0.60) | (0.60) | (0.45) | (0.52) | (0.86) |
| EBITDA margin | -257.1% | -434.6% | -260.9% | -1000.0% | -500.0% | -305.9% | - |
| Profit before tax | (1.65) | (0.68) | (0.65) | (5.99) | (10.39) | (10.43) | (10.96) |
| Net profit | (1.65) | (0.68) | (0.65) | (5.99) | (10.39) | (10.43) | (10.96) |
| Net profit margin | -785.7% | -261.5% | -282.6% | -9983.3% | - | -6135.3% | - |
| EPS (₹) | (0.22) | (0.09) | (0.09) | (0.79) | (1.37) | (1.38) | (1.45) |
| Balance sheet | |||||||
| Total assets | - | 140 | 140 | 140 | 145 | 149 | 159 |
| Net worth | - | 10.03 | 10.71 | 11.37 | 17.38 | 22.24 | 32.67 |
| Total debt | - | 14.52 | 14.00 | 13.11 | 12.01 | 11.33 | 10.33 |
| Cash & bank | - | 0.28 | 0.01 | 0.00 | 0.02 | 0.02 | 0.04 |
| Net working capital | - | (3.06) | (1.11) | (1.26) | (1.26) | (6.74) | (6.96) |
| Cash flow | |||||||
| Cash from operations | - | 1.20 | 0.00 | 0.00 | 0.10 | 0.01 | 0.14 |
| Cash from investing | - | (1.70) | 0.00 | (0.01) | (0.10) | (0.03) | 0.00 |
| Cash from financing | - | 0.78 | 0.00 | 0.00 | 0.00 | 0.00 | (0.20) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.08 | 0.08 | 0.06 |
| Revenue growth (YoY) | +20.0% | -37.5% | -37.5% | -16.7% | 0.0% | - | - | - |
| Other income | 0.00 | 0.15 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.04 |
| EBITDA | (0.06) | (0.28) | (0.06) | (0.08) | (0.14) | (0.54) | (0.09) | (0.08) |
| EBITDA margin | -100.0% | -560.0% | -120.0% | -160.0% | -280.0% | -675.0% | -112.5% | -133.3% |
| Depreciation | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.02 | 0.02 | 0.02 |
| Interest | 0.29 | 0.28 | 0.27 | 0.26 | 0.25 | 0.19 | 0.02 | 0.02 |
| Profit before tax | (0.39) | (0.46) | (0.38) | (0.39) | (0.44) | (0.71) | (0.09) | (0.08) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | (0.39) | (0.46) | (0.38) | (0.39) | (0.44) | (0.71) | (0.09) | (0.08) |
| EPS (₹) | (0.05) | (0.06) | (0.05) | (0.05) | (0.06) | (0.09) | (0.01) | (0.01) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.21 | 0.26 | 0.23 | 0.06 | 0.09 | 0.17 | 0.00 |
| Revenue growth | -19.2% | +13.0% | +283.3% | -33.3% | -47.1% | - | - |
| EBITDA | (0.54) | (1.13) | (0.60) | (0.60) | (0.45) | (0.52) | (0.86) |
| EBITDA margin | -257.1% | -434.6% | -260.9% | -1000.0% | -500.0% | -305.9% | - |
| Profit before tax | (1.65) | (0.68) | (0.65) | (5.99) | (10.39) | (10.43) | (10.96) |
| Net profit | (1.65) | (0.68) | (0.65) | (5.99) | (10.39) | (10.43) | (10.96) |
| Net profit margin | -785.7% | -261.5% | -282.6% | -9983.3% | - | -6135.3% | - |
| EPS (₹) | (0.22) | (0.09) | (0.09) | (0.79) | (1.37) | (1.38) | (1.45) |
| Balance sheet | |||||||
| Total assets | - | 29.99 | 30.33 | 30.29 | 35.37 | 39.72 | 49.32 |
| Net worth | - | (7.55) | (6.87) | (6.21) | (0.20) | 4.66 | 15.10 |
| Total debt | - | 14.52 | 14.00 | 13.12 | 12.02 | 11.33 | 10.33 |
| Cash & bank | - | 0.28 | 0.01 | 0.00 | 0.02 | 0.01 | 0.04 |
| Net working capital | - | (2.96) | (1.02) | (1.16) | (1.16) | (6.64) | (6.86) |
| Cash flow | |||||||
| Cash from operations | - | 1.20 | 0.00 | 0.00 | 0.10 | 0.01 | 0.14 |
| Cash from investing | - | (1.70) | 0.00 | (0.01) | (0.10) | (0.04) | 0.00 |
| Cash from financing | - | 0.78 | 0.00 | 0.00 | 0.00 | 0.00 | (0.20) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.08 | 0.08 | 0.06 |
| Revenue growth (YoY) | +20.0% | -37.5% | -37.5% | -16.7% | 0.0% | - | - | - |
| Other income | 0.00 | 0.15 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.04 |
| Total expenses | 0.12 | 0.33 | 0.11 | 0.13 | 0.19 | 0.62 | 0.17 | 0.14 |
| EBITDA | (0.06) | (0.28) | (0.06) | (0.08) | (0.14) | (0.54) | (0.09) | (0.08) |
| EBITDA margin | -100.0% | -560.0% | -120.0% | -160.0% | -280.0% | -675.0% | -112.5% | -133.3% |
| Depreciation | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.02 | 0.02 | 0.02 |
| Interest | 0.29 | 0.28 | 0.27 | 0.26 | 0.25 | 0.19 | 0.02 | 0.02 |
| Profit before tax | (0.39) | (0.46) | (0.38) | (0.39) | (0.44) | (0.71) | (0.09) | (0.08) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.08 | 0.08 | 0.06 |
| Revenue growth (YoY) | +20.0% | -37.5% | -37.5% | -16.7% | 0.0% | - | - | - |
| Other income | 0.00 | 0.15 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.04 |
| EBITDA | (0.06) | (0.28) | (0.06) | (0.08) | (0.14) | (0.54) | (0.09) | (0.08) |
| EBITDA margin | -100.0% | -560.0% | -120.0% | -160.0% | -280.0% | -675.0% | -112.5% | -133.3% |
| Depreciation | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.02 | 0.02 | 0.02 |
| Interest | 0.29 | 0.28 | 0.27 | 0.26 | 0.25 | 0.19 | 0.02 | 0.02 |
| Profit before tax | (0.39) | (0.46) | (0.38) | (0.39) | (0.44) | (0.71) | (0.09) | (0.08) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | (0.39) | (0.46) | (0.38) | (0.39) | (0.44) | (0.71) | (0.09) | (0.08) |
| EPS (₹) | (0.05) | (0.06) | (0.05) | (0.05) | (0.06) | (0.09) | (0.01) | (0.01) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.21 | 0.26 | 0.23 | 0.06 | 0.09 | 0.17 | 0.00 |
| Revenue growth | -19.2% | +13.0% | +283.3% | -33.3% | -47.1% | - | - |
| Other income | 0.15 | 0.78 | 0.18 | 0.18 | 0.21 | 0.27 | 0.18 |
| Total expenses | 0.75 | 1.39 | 0.83 | 0.66 | 0.54 | 0.69 | 0.86 |
| Employee cost | 0.00 | 0.31 | 0.31 | 0.30 | 0.29 | 0.25 | 0.29 |
| EBITDA | (0.54) | (1.13) | (0.60) | (0.60) | (0.45) | (0.52) | (0.86) |
| EBITDA margin | -257.1% | -434.6% | -260.9% | -1000.0% | -500.0% | -305.9% | - |
| Depreciation | 0.20 | 0.09 | 0.09 | 4.95 | 9.92 | 9.91 | 9.90 |
| Interest | 1.06 | 0.24 | 0.14 | 0.62 | 0.23 | 0.27 | 0.38 |
| Profit before tax | (1.65) | (0.68) | (0.65) | (5.99) | (10.39) | (10.43) | (10.96) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | (1.65) | (0.68) | (0.65) | (5.99) | (10.39) | (10.43) | (10.96) |
| Net profit margin | -785.7% | -261.5% | -282.6% | -9983.3% | - | -6135.3% | - |
| EPS (₹) | (0.22) | (0.09) | (0.09) | (0.79) | (1.37) | (1.38) | (1.45) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
| Reserves & surplus | - | (65.74) | (65.06) | (64.40) | (58.39) | (53.53) | (43.10) |
| Shareholders' funds (net worth) | - | 10.03 | 10.71 | 11.37 | 17.38 | 22.24 | 32.67 |
| Minority interest | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | - | 6.10 | 4.93 | 4.80 | 4.62 | 4.39 | 4.13 |
| Unsecured loans | - | 8.42 | 9.07 | 8.31 | 7.39 | 6.94 | 6.20 |
| Total debt | - | 14.52 | 14.00 | 13.11 | 12.01 | 11.33 | 10.33 |
| Total liabilities | - | 140 | 140 | 140 | 145 | 149 | 159 |
| Assets | |||||||
| Gross block | - | 109 | 108 | 108 | 108 | 108 | 108 |
| Net block | - | 7.97 | 6.36 | 6.45 | 11.40 | 21.33 | 31.20 |
| Capital work in progress | - | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 |
| Investments | - | 0.10 | 0.10 | 0.10 | 0.10 | 0.00 | 0.00 |
| Inventories | - | 0.03 | 0.03 | 0.03 | 0.09 | 0.02 | 0.04 |
| Sundry debtors | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Cash & bank balances | - | 0.28 | 0.01 | 0.00 | 0.02 | 0.02 | 0.04 |
| Loans & advances | - | 0.94 | 1.06 | 1.00 | 0.58 | 0.60 | 0.60 |
| Total current assets | - | 1.26 | 1.11 | 1.04 | 0.70 | 0.65 | 0.69 |
| Total current liabilities | - | 4.32 | 2.22 | 2.30 | 1.96 | 7.39 | 7.65 |
| Net working capital | - | (3.06) | (1.11) | (1.26) | (1.26) | (6.74) | (6.96) |
| Total assets | - | 140 | 140 | 140 | 145 | 149 | 159 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 0.01 | 0.00 | 0.02 | 0.01 | 0.04 | 0.10 |
| Net cash from operating activities | - | 1.20 | 0.00 | 0.00 | 0.10 | 0.01 | 0.14 |
| Net cash from investing activities | - | (1.70) | 0.00 | (0.01) | (0.10) | (0.03) | 0.00 |
| Net cash from financing activities | - | 0.78 | 0.00 | 0.00 | 0.00 | 0.00 | (0.20) |
| Net change in cash | - | 0.28 | 0.00 | (0.01) | 0.00 | (0.01) | (0.06) |
| Closing cash | - | 0.28 | 0.01 | 0.00 | 0.02 | 0.02 | 0.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -19.2% | +13.0% | +283.3% | -33.3% | -47.1% | - | - |
| EBITDA growth | +52.2% | -88.3% | 0.0% | -33.3% | +13.5% | +39.5% | - |
| PBT growth | -142.7% | -4.6% | +89.2% | +42.4% | +0.4% | +4.8% | -24.7% |
| Net income growth | -142.7% | -4.6% | +89.2% | +42.4% | +0.4% | +4.8% | - |
| Revenue CAGR (3Y) | +51.8% | +42.4% | +10.6% | - | +8.7% | +12.3% | -100.0% |
| EBITDA CAGR (3Y) | -3.5% | +35.9% | +4.9% | -11.3% | -12.9% | -37.2% | -30.5% |
| Profitability & leverage | |||||||
| Net income margin | -785.7% | -261.5% | -282.6% | -9983.3% | - | -6135.3% | - |
| Return on capital employed | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Return on net worth | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt / equity | - | 1.38 | 1.23 | 0.87 | 0.59 | 0.39 | 0.26 |
| Long-term debt / equity | - | 0.54 | 0.45 | 0.34 | 0.24 | 0.16 | 0.11 |
| Interest cover | -143.24 | -19.67 | -20.29 | -11.17 | -2.22 | -2.59 | -3.53 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | 8.67 | 7.67 | 1.00 | 1.64 | 5.67 | 0.00 |
| Debtors turnover | - | 26.00 | 23.00 | 6.00 | 9.00 | 17.00 | 0.00 |
| EPS (₹) | (0.22) | (0.09) | (0.09) | (0.79) | (1.37) | (1.38) | (1.45) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 1.32 | 1.41 | 1.50 | 2.29 | 2.94 | 4.31 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.08 | 0.08 | 0.06 |
| Revenue growth (YoY) | +20.0% | -37.5% | -37.5% | -16.7% | 0.0% | - | - | - |
| Other income | 0.00 | 0.15 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.04 |
| Total expenses | 0.12 | 0.33 | 0.11 | 0.13 | 0.19 | 0.62 | 0.17 | 0.14 |
| EBITDA | (0.06) | (0.28) | (0.06) | (0.08) | (0.14) | (0.54) | (0.09) | (0.08) |
| EBITDA margin | -100.0% | -560.0% | -120.0% | -160.0% | -280.0% | -675.0% | -112.5% | -133.3% |
| Depreciation | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.02 | 0.02 | 0.02 |
| Interest | 0.29 | 0.28 | 0.27 | 0.26 | 0.25 | 0.19 | 0.02 | 0.02 |
| Profit before tax | (0.39) | (0.46) | (0.38) | (0.39) | (0.44) | (0.71) | (0.09) | (0.08) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.21 | 0.26 | 0.23 | 0.06 | 0.09 | 0.17 | 0.00 |
| Revenue growth | -19.2% | +13.0% | +283.3% | -33.3% | -47.1% | - | - |
| Other income | 0.15 | 0.78 | 0.18 | 0.18 | 0.21 | 0.27 | 0.18 |
| Total expenses | 0.75 | 1.39 | 0.83 | 0.66 | 0.54 | 0.69 | 0.86 |
| Employee cost | 0.00 | 0.31 | 0.31 | 0.30 | 0.29 | 0.25 | 0.29 |
| EBITDA | (0.54) | (1.13) | (0.60) | (0.60) | (0.45) | (0.52) | (0.86) |
| EBITDA margin | -257.1% | -434.6% | -260.9% | -1000.0% | -500.0% | -305.9% | - |
| Depreciation | 0.20 | 0.09 | 0.09 | 4.95 | 9.92 | 9.91 | 9.90 |
| Interest | 1.06 | 0.24 | 0.14 | 0.62 | 0.23 | 0.27 | 0.38 |
| Profit before tax | (1.65) | (0.68) | (0.65) | (5.99) | (10.39) | (10.43) | (10.96) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | (1.65) | (0.68) | (0.65) | (5.99) | (10.39) | (10.43) | (10.96) |
| Net profit margin | -785.7% | -261.5% | -282.6% | -9983.3% | - | -6135.3% | - |
| EPS (₹) | (0.22) | (0.09) | (0.09) | (0.79) | (1.37) | (1.38) | (1.45) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
| Reserves & surplus | - | (83.32) | (82.64) | (81.98) | (75.97) | (71.11) | (60.67) |
| Shareholders' funds (net worth) | - | (7.55) | (6.87) | (6.21) | (0.20) | 4.66 | 15.10 |
| Secured loans | - | 6.10 | 4.93 | 4.80 | 4.62 | 4.39 | 4.13 |
| Unsecured loans | - | 8.42 | 9.07 | 8.32 | 7.40 | 6.94 | 6.20 |
| Total debt | - | 14.52 | 14.00 | 13.12 | 12.02 | 11.33 | 10.33 |
| Total liabilities | - | 29.99 | 30.33 | 30.29 | 35.37 | 39.72 | 49.32 |
| Assets | |||||||
| Gross block | - | 109 | 108 | 108 | 108 | 108 | 108 |
| Net block | - | 7.96 | 6.36 | 6.45 | 11.40 | 21.33 | 31.20 |
| Capital work in progress | - | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 |
| Investments | - | 0.10 | 0.10 | 0.11 | 0.11 | 0.01 | 0.00 |
| Inventories | - | 0.03 | 0.03 | 0.03 | 0.09 | 0.02 | 0.04 |
| Sundry debtors | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank balances | - | 0.28 | 0.01 | 0.00 | 0.02 | 0.01 | 0.04 |
| Loans & advances | - | 0.94 | 1.06 | 1.00 | 0.58 | 0.60 | 0.60 |
| Total current assets | - | 1.25 | 1.10 | 1.03 | 0.69 | 0.63 | 0.68 |
| Total current liabilities | - | 4.21 | 2.12 | 2.19 | 1.85 | 7.27 | 7.54 |
| Net working capital | - | (2.96) | (1.02) | (1.16) | (1.16) | (6.64) | (6.86) |
| Total assets | - | 29.99 | 30.33 | 30.29 | 35.37 | 39.72 | 49.32 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 0.01 | 0.00 | 0.02 | 0.01 | 0.04 | 0.10 |
| Net cash from operating activities | - | 1.20 | 0.00 | 0.00 | 0.10 | 0.01 | 0.14 |
| Net cash from investing activities | - | (1.70) | 0.00 | (0.01) | (0.10) | (0.04) | 0.00 |
| Net cash from financing activities | - | 0.78 | 0.00 | 0.00 | 0.00 | 0.00 | (0.20) |
| Net change in cash | - | 0.28 | 0.00 | (0.01) | 0.00 | (0.02) | (0.06) |
| Closing cash | - | 0.28 | 0.01 | 0.00 | 0.02 | 0.01 | 0.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -19.2% | +13.0% | +283.3% | -33.3% | -47.1% | - | - |
| EBITDA growth | +52.2% | -88.3% | 0.0% | -33.3% | +13.5% | +39.5% | - |
| PBT growth | -142.7% | -4.6% | +89.2% | +42.4% | +0.4% | +4.8% | -24.7% |
| Net income growth | -142.7% | -4.6% | +89.2% | +42.4% | +0.4% | +4.8% | - |
| Revenue CAGR (3Y) | +51.8% | +42.4% | +10.6% | - | +8.7% | +12.3% | -100.0% |
| EBITDA CAGR (3Y) | -3.5% | +35.9% | +4.9% | -11.3% | -12.9% | -37.2% | -30.5% |
| Profitability & leverage | |||||||
| Net income margin | -785.7% | -261.5% | -282.6% | -9983.3% | - | -6135.3% | - |
| Return on capital employed | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Return on net worth | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt / equity | - | 0.00 | 0.00 | 0.00 | 5.23 | 1.10 | 0.47 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.00 | 2.09 | 0.45 | 0.20 |
| Interest cover | -143.24 | -19.67 | -20.29 | -11.17 | -2.22 | -2.59 | -3.53 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | 8.67 | 7.67 | 1.00 | 1.64 | 5.67 | 0.00 |
| Debtors turnover | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS (₹) | (0.22) | (0.09) | (0.09) | (0.79) | (1.37) | (1.38) | (1.45) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | (1.00) | (0.91) | (0.82) | (0.03) | 0.62 | 1.99 |
To see the full year-wise statements and ratios of Transgene Biotek Limited., buy the company report.
Board of directors of Transgene Biotek Limited.
Transgene Biotek Limited has 4 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kollipara Koteswara Rao | Managing Director | 04 Mar 2020 | 6 Years 7 Months | Current |
| Sujana Kadiam | Director | 17 Apr 2015 | 11 Years 6 Months | Current |
| Santhosh Kumar Also directs: Sanghi Spinners India Limited | Director | 12 Nov 2019 | 6 Years 11 Months | Current |
| Swetha Marri | Director | 03 Jun 2020 | 6 Years 4 Months | Current |
Peer comparison
Transgene Biotek Limited. is compared with the 3 companies closest to it by revenue in the Biotechnology industry (Biotechnology), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Dozo Pharma Private Limited | ₹1.06 Cr (FY 2024) | 86.0% | Mohali, Punjab, India | |||
| Pusilin Biotechnology Private Limited | ₹1.03 Cr (FY 2024) | -83.0% | Kanpur, Uttar Pradesh, India | |||
| Amines Biotech Private Limited | ₹1.03 Cr (FY 2025) | -5.0% | Vadodara, Gujarat, India | |||
| Transgene Biotek Limited.this company | ₹21 Lakh (FY 2026) | -₹1.65 Cr | -19.2% | Ida Bollaram, Telangana, India |
To see the full peer comparison of Transgene Biotek Limited., buy the company report.
Auditor
Transgene Biotek Limited. is audited by VASAVI & CO for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| VASAVI & CO | FY 2024 | 020965S |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 23.60%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 76.40%.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 23.60% | 23.60% | 23.60% | 23.60% |
| Public | 76.40% | 76.40% | 76.40% | 76.40% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 11 Apr 2025 | 101095247 | Others | ₹1.5 Cr | Open | |
| 30 Jan 2025 | 101044763 | Others | ₹6 Cr | Open | |
| 08 Apr 2010 | 10212693 | Department of Biotechnology | ₹5.07 Cr | Open | |
| 30 Jul 2008 | 10116760 | Ge Capital Services India | ₹8.63 Lakh | Satisfied | |
| 23 May 2007 | 10052981 | Union Bank of India | ₹3.92 Cr | Satisfied |
To see the full charge records of Transgene Biotek Limited., buy the company report.
Total charge records: 10 View all charges
Deals & funding
Transgene Biotek Limited. has 56 deals on record (54 market trades, 1 acquisition, 1 funding round); the latest was in December 2023.
Deals on record (5 of 56)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2023 | Market trade | ₹73.1 Lakh | Buyer: Sahasrar Capital Private Limited , an individual Seller: Geetanjali Investments |
| Nov 2023 | Market trade | ₹65.2 Lakh | Buyer: Sahasrar Capital Private Limited Seller: Geetanjali Investments |
| Mar 2014 | Market trade | ₹26.9 Lakh | Buyer: SH. As Enterprises LLP |
| Nov 2012 | Market trade | ₹77.8 Lakh | Buyer: Baba Bhoothnath Nirman Private Limited Seller: Baba Bhoothnath Nirman Private Limited |
| Oct 2012 | Market trade | ₹70.1 Lakh | Buyer: an individual Seller: Quant Broking Private Limited |
To see the full deal history of Transgene Biotek Limited., buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Transgene Biotek Limited. has 41 court cases on record: 23 filed by Transgene Biotek Limited, 18 filed against it. 3 cases are pending and 38 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 33 | 14 | 2 |
| District courts | 8 | 4 | 1 |
Cases on record (5 of 41)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Medak, Telangana | Civil suit | Filed by the company against CH. Krishna Abhiram Managing Partner Phanes Biomax LLP, and 1 other | Disposed |
| High Court, TAMIL NADU | Appeal | Filed against the company by M/S.Integrated Finance Co.Ltd. | Disposed |
| High Court, TELANGANA | Revision petition | Filed against the company by M/A.Serum Institute of India Ltd | Disposed |
| Bombay High Court | Court case (SJ) | Filed against the company by Ankit Tradesec Ltd | Disposed |
| Bombay High Court | Court case (SS) | Filed against the company by Ankit Tradesec Ltd | Disposed |
To see the full case history of Transgene Biotek Limited., buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Transgene Biotek Limited.; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Transgene Biotek Limited has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Peroral Bio Private Limited | U24230TG2020PTC147169 |
To see the full group structure of Transgene Biotek Limited., buy the company report.
GST
Transgene Biotek Limited has 4 GST registrations: 1 active and 3 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AABCT3840P2ZX | Telangana | Active | 19 Aug 2017 |
To see the full GST registrations and return filing status of Transgene Biotek Limited., buy the company report.
Recent activity
Transgene Biotek Limited. has 20 board changes on record since 1996: 12 appointments and 8 cessations. The latest: Swetha Marri was appointed as Director on 03 Jun 2020.
31 earlier events are in the company report.
News
Frequently asked questions
Transgene Biotek Limited is an active public limited company based in Ida Bollaram, Telangana, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 01 March 1990 (36+ years old) and is registered under CIN L85195TG1990PLC011065. Listed on BSE: 526139.
Transgene Biotek Limited reported revenue of ₹21 Lakh for FY 2025-26 (down 19.2% YoY) based on consolidated financials.
Transgene Biotek Limited has 4 current directors:
- Kollipara Koteswara Rao - Managing Director
- Sujana Kadiam - Director
- Santhosh Kumar - Director
- Swetha Marri - Director
The latest financial statements of Transgene Biotek Limited on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 December 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Transgene Biotek Limited is 36AABCT3840P2ZX, registered in Telangana. The company has 4 GST registrations in all, of which 1 is active and 3 are cancelled or inactive.
The CIN (Corporate Identification Number) of Transgene Biotek Limited is L85195TG1990PLC011065. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Transgene Biotek Limited is listed on BSE with code 526139.
Transgene Biotek Limited has 41 court cases on record: 23 filed by the company and 18 filed against it. 3 are pending. Most are in the high courts.
Transgene Biotek Limited was incorporated on 01 March 1990, making it 36+ years old. It is registered with the Registrar of Companies, Hyderabad.
Transgene Biotek Limited has 56 deals on record (54 market trades, 1 acquisition, 1 funding round); the latest was in December 2023.
The peers of Transgene Biotek Limited by revenue are Dozo Pharma Private Limited, Pusilin Biotechnology Private Limited, Amines Biotech Private Limited, all in the Biotechnology industry (Biotechnology), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).